Cytokinetics, Incorporated

NasdaqGS:CYTK 주식 보고서

시가총액: US$6.3b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cytokinetics 관리

관리 기준 확인 3/4

Cytokinetics' CEO는 Robert Blum, Feb2006 에 임명되었습니다 의 임기는 18.33 년입니다. 총 연간 보상은 $ 8.75M, 9% 로 구성됩니다. 9% 급여 및 91% 보너스(회사 주식 및 옵션 포함). 는 $ 16.38M 가치에 해당하는 회사 주식의 0.27% 직접 소유합니다. 16.38M. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 13.6 년입니다.

주요 정보

Robert Blum

최고 경영자

US$8.8m

총 보상

CEO 급여 비율9.0%
CEO 임기18.4yrs
CEO 소유권0.3%
경영진 평균 재임 기간3.3yrs
이사회 평균 재임 기간13.7yrs

최근 관리 업데이트

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

May 09
Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

Recent updates

Cytokinetics Decides To Go It Alone

May 24

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

May 09
Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

Cytokinetics, Incorporated: Buyout Speculation Persists

Apr 01

Cytokinetics: CEO Talks Down Buyout Prospects

Mar 16

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Jan 12

An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued

Oct 05
An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued

Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week

May 07
Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week

Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week

Mar 03
Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week

CEO 보상 분석

Robert Blum 의 보수는 Cytokinetics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$531m

Dec 31 2023US$9mUS$790k

-US$526m

Sep 30 2023n/an/a

-US$527m

Jun 30 2023n/an/a

-US$540m

Mar 31 2023n/an/a

-US$431m

Dec 31 2022US$9mUS$742k

-US$389m

Sep 30 2022n/an/a

-US$282m

Jun 30 2022n/an/a

-US$216m

Mar 31 2022n/an/a

-US$258m

Dec 31 2021US$6mUS$709k

-US$215m

Sep 30 2021n/an/a

-US$229m

Jun 30 2021n/an/a

-US$156m

Mar 31 2021n/an/a

-US$135m

Dec 31 2020US$5mUS$682k

-US$127m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$140m

Mar 31 2020n/an/a

-US$132m

Dec 31 2019US$3mUS$656k

-US$122m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$110m

Mar 31 2019n/an/a

-US$105m

Dec 31 2018US$3mUS$630k

-US$106m

Sep 30 2018n/an/a

-US$120m

Jun 30 2018n/an/a

-US$131m

Mar 31 2018n/an/a

-US$132m

Dec 31 2017US$3mUS$612k

-US$128m

보상 대 시장: Robert 의 총 보상 ($USD 8.75M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 8.45M ).

보상과 수익: 회사가 수익성이 없는 동안 Robert 의 보상이 증가했습니다.

CEO

Robert Blum (60 yo)

18.4yrs

테뉴어

US$8,751,057

보상

Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and served as its Principal Financial Officer until May 08, 2024. Mr. Blum p...

리더십 팀

이름위치테뉴어보상소유권
Robert Blum
CEO, President & Director18.4yrsUS$8.75m0.25%
$ 15.9m
Robert Wong
VP & Chief Accounting Officer5.2yrsUS$1.04m0.0064%
$ 404.8k
Fady Malik
Executive Vice President of Research & Development12.1yrsUS$4.44m0.070%
$ 4.4m
Andrew Callos
Executive VP & Chief Commercial Officer3.3yrsUS$3.20m0.021%
$ 1.4m
James Spudich
Co-Founder & Member of Scientific Advisory Board26.9yrsUS$21.94k데이터 없음
Sung Lee
Executive VP & CFOless than a year데이터 없음데이터 없음
Jeff Lotz
Vice President of Sales & Operations2.8yrs데이터 없음데이터 없음
Matt Yang
Vice President of Corporate Finance and Financial Planning & Analysisless than a year데이터 없음데이터 없음
Steven Cook
Senior Vice President of Global Supply Chain Operations & Technical Operationsno data데이터 없음데이터 없음
Kari Loeser
VP & Chief Compliance Officer2.7yrs데이터 없음데이터 없음
John Faurescu
VP, Associate General Counsel & Corporate Secretaryno data데이터 없음데이터 없음
Scott Jordan
Senior Vice President of Global Marketing & Commercial Strategy3.2yrs데이터 없음데이터 없음

3.3yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: CYTK 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Robert Blum
CEO, President & Director17.5yrsUS$8.75m0.25%
$ 15.9m
James Spudich
Co-Founder & Member of Scientific Advisory Boardno dataUS$21.94k데이터 없음
B. Parshall
Independent Director11.4yrsUS$529.02k0.013%
$ 812.8k
Santo Costa
Independent Director13.7yrsUS$524.02k0.013%
$ 812.8k
James H. Sabry
Co-Founder & Chairman of Scientific Advisory Board16.3yrsUS$41.50k데이터 없음
Nancy Wysenski
Independent Director3.7yrsUS$519.02k0.015%
$ 929.3k
John Henderson
Independent Chairman15.4yrsUS$559.02k0.028%
$ 1.7m
John Lowe
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Thomas Pollard
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
David Morgans
Member of Scientific Advisory Board8yrsUS$942.23k데이터 없음
Lawrence S. Goldstein
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
John Solaro
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

13.7yrs

평균 재임 기간

70.5yo

평균 연령

경험이 풍부한 이사회: CYTK 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 13.6 년).